# US Hereditary Angioedema Therapeutics Market > US Hereditary Angioedema Therapeutics Market Research Report: Size, Share, Trend Analysis By Types (Type I, Type II), By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others), By Treatment (Prophylaxis - Long-term Prophylaxis, Short-term Prophylaxis, On-demand), By Route of Administration (Intravenous, Subcutaneous, Oral) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.1% - **2024:** $ 1,761.4 Million - **2025:** $ 1,833.62 Million - **2035:** $ 2,739.7 Million - **Key Players:** Takeda Pharmaceutical Company Limited (JP), CSL Behring (US), Shire (US), Pharming Group N.V. (NL), BioCryst Pharmaceuticals, Inc. (US), Sobi (SE), Ferring Pharmaceuticals (CH), Grifols S.A. (ES) **Report ID:** MRFR/HC/15214-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-hereditary-angioedema-therapeutics-market-16742 --- ## Market Summary ## **US Hereditary Angioedema Therapeutics Market Overview** As per MRFR analysis, the US Hereditary Angioedema Therapeutics Market Size was estimated at 1.43 (USD Billion) in 2023. The US Hereditary Angioedema Therapeutics Market Industry is expected to grow from 1.65 (USD Billion) in 2024 to 9.13 (USD Billion) by 2035. The US Hereditary Angioedema Therapeutics Market CAGR (growth rate) is expected to be around 16.827% during the forecast period (2025 - 2035). ### **Key US Hereditary Angioedema Therapeutics Market Trends Highlighted** The US Hereditary Angioedema (HAE) Therapeutics Market is currently witnessing notable trends driven by an increasing awareness of HAE and a rise in the diagnosis of this rare condition. Key market drivers include the availability of new and advanced treatment options, such as C1-esterase inhibitor therapies and bradykinin receptor antagonists, which have significantly improved patient outcomes. Additionally, the emphasis on personalized medicine is helping tailor treatments to individual patient needs, enhancing overall therapeutic efficacy. Opportunities in this market are expanding as healthcare providers and pharmaceutical companies focus on developing innovative therapies exceeding current treatment capabilities. The growing population of patients diagnosed with HAE in the US, which is estimated to be around 6,000 to 10,000 individuals, presents untapped potential for new drug development and therapies. There is also an increasing participation in clinical trials aimed at finding new treatments, which can provide patients with access to cutting-edge therapies while also advancing knowledge in this area. Recent trends indicate that patient advocacy groups are playing a significant role in raising awareness and improving access to treatments. The collaboration between these groups and healthcare professionals is helping facilitate the understanding of HAE’s impact and promote timely diagnosis. Furthermore, the US Food and Drug Administration's push for expedited drug approval processes is enabling quicker access to innovative therapies for patients, showcasing the commitment to enhancing care standards in the realm of hereditary angioedema treatment. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Hereditary Angioedema Therapeutics Market Drivers** ### **Increasing Awareness and Diagnosis of Hereditary Angioedema** In the United States, the awareness and understanding of Hereditary Angioedema (HAE) have significantly improved over the past decade. The creation of awareness campaigns by organizations such as the US Hereditary Angioedema Association and the National Institutes of Health has led to better recognition of symptoms and conditions associated with HAE. According to the Health Resources and Services Administration, approximately 1 in 50,000 individuals in the US are diagnosed with HAE, up from historical estimates of 1 in 150,000. This increase in diagnosed cases is driving the demand for therapeutics and creating a growing US Hereditary Angioedema Therapeutics Market Industry, as more patients seek effective treatment options and management strategies. With more healthcare practitioners educated on the condition, early diagnosis can lead to timely interventions, reduced emergency room visits, and improved patient outcomes, further expanding the market. ### **Advancements in Therapeutics and Treatment Options** The US Hereditary Angioedema Therapeutics Market Industry is experiencing substantial growth primarily due to the advancements in therapeutics and the introduction of novel treatment options. The last few years have seen new drugs, such as C1 Inhibitors and bradykinin inhibitors, receiving approval from the U.S. Food and Drug Administration. Currently, nearly eight different products are approved specifically for treating HAE in the US, providing tailored treatment approaches for diverse patient needs. Moreover, ongoing Research and Development conducted by major pharmaceutical companies, including Shire and CSL Behring, has reported a remarkable increase in treatment outcomes, with some therapies showing over 75% efficacy in reducing HAE attacks. This continued innovation is expected to propel market growth and increase accessibility to effective treatments across various demographics. ### **Growing Patient Population and Prevalence of HAE** The US **[Hereditary Angioedema Therapeutics Market](../../../reports/hereditary-angioedema-therapeutics-market-12163)** Industry is also benefiting from a growing patient population suffering from HAE. The U.S. Census Bureau indicates that the population in the US is expected to exceed 350 million by 2030, with an increasing proportion of individuals at risk for HAE. A study published in the Journal of Allergy and Clinical Immunology estimates that the prevalence of HAE may rise by up to 20% in the coming decade due to improved genetic testing methods. As more people become aware of their genetic predisposition, the market demand for effective therapeutics is anticipated to rise sharply. This growing patient base will not only present opportunities for existing companies but will also attract new entrants into the US Hereditary Angioedema Therapeutics Market Industry. ## **US Hereditary Angioedema Therapeutics Market Segment Insights** ### **Hereditary Angioedema Therapeutics Market Type Insights** The Type segment of the US Hereditary Angioedema Therapeutics Market is crucial in understanding the landscape of treatments available for this rare genetic disorder. The market is primarily categorized into Type I and Type II, each with unique characteristics and treatment requirements. Type I is characterized by a deficiency of the C1 esterase inhibitor, which leads to uncontrolled inflammation and swelling; hence, the demand for effective therapies has surged in recent years. This type accounts for the majority of hereditary angioedema cases in the US, making it a significant focus for research and therapeutic developments. Patients often require on-demand treatment during acute attacks, which has spurred innovation in targeted therapies and the emergence of novel medications tailored specifically for this group. On the other hand, Type II, although less common, is marked by the presence of dysfunctional C1 inhibitors, which can also lead to life-threatening episodes of swelling. The pathophysiology of Type II is similar to Type I, but the management strategies may differ, creating a distinct avenue for therapeutic options and challenges in care. Both types present unique treatment paradigms and influence the US Hereditary Angioedema Therapeutics Market dynamics substantially. The increase in awareness and diagnosis of hereditary angioedema has improved patient outcomes, prompting more investment in Research and Development to explore potential biological therapies and genetic editing technologies. Overall, the Type segment represents a vital component of the US Hereditary Angioedema Therapeutics Market, reflecting the complexity of the condition and the ongoing need for effective management strategies. The growing patient population and advancements in understanding the genetic basis of these disorders fuel demand for innovative solutions. As healthcare providers continue to recognize the varied presentations and treatment needs of Type I and Type II, the market is expected to evolve accordingly, aligning with emerging trends in precision medicine and personalized therapeutic approaches. The emphasis on patient-centered care will likely enhance therapeutic adherence, leading to better disease management and quality of life for individuals living with hereditary angioedema. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Hereditary Angioedema Therapeutics Market Drug Class Insights** The US Hereditary Angioedema Therapeutics Market within the Drug Class segment is witnessing significant attention from stakeholders, driven by the increasing prevalence of hereditary angioedema (HAE) and the growing demand for effective treatments. The segmentation includes various components such as C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others. C1 Esterase Inhibitors are crucial as they directly address the deficiency in patients and have historically been a standard of care, significantly contributing to improving patient outcomes. Selective Bradykinin B2 Receptor Antagonists are gaining traction due to their innovative approach in managing angioedema episodes, providing an essential alternative to traditional therapies. Kallikrein Inhibitors represent a newer class, showing promise in reducing the frequency and severity of HAE attacks, reflecting ongoing advancements in Research and Development within the industry. Others in this market category include a range of products that utilize different mechanisms of action to ensure effective management, appealing to a broader patient demographic. Overall, the growth of the US Hereditary Angioedema Therapeutics Market segmentation reflects a trend toward more personalized and effective treatment options for patients suffering from this condition. ### **Hereditary Angioedema Therapeutics Market Treatment Insights** The Treatment segment of the US Hereditary Angioedema Therapeutics Market plays a crucial role in managing this rare genetic condition characterized by recurrent episodes of severe swelling. Within this segment, Prophylaxis is a vital approach used to prevent attacks, and it includes Long-term Prophylaxis, Short-term Prophylaxis, and On-demand therapies. Long-term Prophylaxis is particularly significant as it helps to minimize the frequency and severity of attacks, which can greatly enhance the quality of life for patients. Short-term Prophylaxis is employed in specific situations, such as before surgical procedures or potential triggers, allowing patients to manage risks effectively. On-demand therapies are designed for immediate relief during acute episodes, emphasizing the need for rapid action to alleviate symptoms. The dominance of these approaches is driven by the rising awareness of hereditary angioedema among healthcare professionals and patients alike, along with advancements in treatment modalities. The US market continues to provide opportunities for innovation in treatment strategies, which is essential for meeting the needs of individuals affected by this complex condition. Overall, the segmentation within the Treatment segment underscores the diverse yet complementary strategies required to tackle hereditary angioedema effectively in the US. ### **Hereditary Angioedema Therapeutics Market Route of Administration Insights** The Route of Administration segment in the US Hereditary Angioedema Therapeutics Market is crucial for determining how therapies are delivered to patients effectively. Among the various options, Intravenous administration provides rapid therapeutic action and is essential for patients experiencing severe attacks, ensuring immediate relief. Subcutaneous delivery is becoming increasingly popular due to its ease of use, allowing patients to self-administer medication at home, thereby enhancing treatment adherence and convenience. Oral administration also plays a significant role, particularly for long-term management, as it appeals to patients' preferences for non-invasive treatment methods. The interplay between these routes addresses diverse patient needs and scenarios, driving innovation and fostering growth in the market. With a growing population affected by hereditary angioedema and advancements in drug formulations, the Route of Administration segment stands out as a key focus area for pharmaceutical companies aiming to expand their offerings and improve patient outcomes. Furthermore, the increasing awareness of hereditary angioedema and ongoing Research and Development efforts are anticipated to bolster these routes, making safe and effective therapies more accessible to patients across the United States. ### **Hereditary Angioedema Therapeutics Market Distribution Channel Insights** The US Hereditary Angioedema Therapeutics Market is primarily segmented through various Distribution Channels, which play a crucial role in ensuring that patients have access to necessary treatments. Hospital Pharmacy is pivotal as it offers specialized medication management and immediate access to therapies for patients receiving treatment in clinical settings. Retail Pharmacy has a substantial presence, providing convenience and accessibility for patients who prefer to obtain their medications within their local communities, making it a favored option for chronic condition management. Meanwhile, Online Pharmacy is gaining significant traction due to the increasing preference for telehealth services and the convenience of home delivery, especially post-pandemic. The rise of digital health solutions has driven a notable shift towards online platforms, enabling patients to bypass traditional hurdles in accessing therapies. All these distribution channels are essential for meeting the diverse needs of patients, ultimately supporting the market growth by enhancing therapeutic reach and improving patient adherence to prescribed regimens in the US. ## **US Hereditary Angioedema Therapeutics Market Key Players and Competitive Insights** The US Hereditary Angioedema Therapeutics Market has become increasingly competitive as pharmaceutical companies strive to address the unmet medical needs of patients suffering from this rare and potentially life-threatening condition. The market is characterized by a range of therapeutic options, including C1-esterase inhibitor therapies, bradykinin receptor antagonists, and other innovative treatments aimed at reducing the frequency and severity of angioedema attacks. The rise in awareness of hereditary angioedema, improved diagnostic techniques, and ongoing research and development efforts contribute to a dynamic landscape where companies are competing for market share and striving to deliver effective solutions that enhance patient outcomes. Regulatory advancements also play a critical role in shaping the competitive environment, facilitating the approval and commercialization of new therapeutics. AstraZeneca holds a notable presence in the US Hereditary Angioedema Therapeutics Market, leveraging its strong research and development capabilities to address this niche therapeutic area. The company's approach is supported by its robust pipeline and commitment to innovation, which enables it to explore novel therapeutic modalities. AstraZeneca's established distribution channels and collaborations with leading healthcare providers reinforce its market position. The company utilizes a patient-centered strategy, focusing on increasing awareness and providing comprehensive support to patients and healthcare professionals, thereby fostering brand loyalty and enhancing treatment adherence. Moreover, AstraZeneca's investment in clinical trials demonstrates its dedication to ensuring the efficacy and safety of its therapies, further solidifying its reputation in the industry. Takeda Pharmaceutical is another key player in the US Hereditary Angioedema Therapeutics Market, recognized for its comprehensive range of treatment options that cater to the needs of patients with this condition. The company's key products include C1-esterase inhibitors and bradykinin receptor antagonists, which have been developed to significantly reduce the frequency of angioedema attacks and improve quality of life. Takeda's commitment to research and development is highlighted by its ongoing investment in clinical trials and its focus on innovation within the hereditary angioedema therapeutic domain. Furthermore, Takeda's strategic mergers and acquisitions have bolstered its portfolio, enabling the company to enhance its market presence and expand its reach within the US region. By combining its operational strengths with a deep understanding of patient needs, Takeda aims to provide effective solutions while fortifying its position in the rapidly evolving landscape of hereditary angioedema therapeutics. ### **Key Companies in the US Hereditary Angioedema Therapeutics Market Include** ## **US Hereditary Angioedema Therapeutics Market Industry Developments** The US Hereditary Angioedema Therapeutics Market has seen significant developments recently. In June 2023, CSL Behring announced progress in its gene therapy development for hereditary angioedema, showcasing advancements in reducing treatment frequency for patients while enhancing efficacy. Takeda Pharmaceutical reported elevated market performance due to the successful launch of its new therapies, which have gained traction among healthcare professionals and patients for their improved safety profiles. In terms of mergers and acquisitions, Emergent BioSolutions completed its acquisition of a small biotech firm focused on rare diseases, including hereditary angioedema, in July 2023. Furthermore, Biocryst Pharmaceuticals achieved a market valuation growth following its innovative product launches; this has solidified its presence in the American market, contributing to an overall market expansion. Over the past two to three years, the market has also seen heightened competition and increased investment in Research and Development as companies such as Amgen and Regeneron Pharmaceuticals emphasize novel therapeutics aimed at improving patient outcomes. Government support through funding for cutting-edge therapies has further stimulated market activity, promising a robust growth landscape for the industry moving forward. ## **US Hereditary Angioedema Therapeutics Market Segmentation Insights** ### **Hereditary Angioedema Therapeutics Market Type Outlook** ### **Hereditary Angioedema Therapeutics Market Drug Class Outlook** ### **Hereditary Angioedema Therapeutics Market Treatment Outlook** ### **Hereditary Angioedema Therapeutics Market Route of Administration Outlook** ### **Hereditary Angioedema Therapeutics Market Distribution Channel Outlook** ## Market Drivers ### Advancements in Biotechnology Technological advancements in biotechnology are significantly influencing the hereditary angioedema-therapeutics market. Innovations in drug development, particularly in biologics and monoclonal antibodies, have led to the creation of targeted therapies that offer improved efficacy and safety profiles. For instance, recent breakthroughs in gene therapy and RNA-based treatments hold promise for long-term management of HAE. The market is projected to witness substantial growth, with estimates indicating a compound annual growth rate (CAGR) of over 15% in the coming years. These advancements not only enhance treatment options but also attract investment from biotech firms, thereby expanding the therapeutic landscape for HAE. ### Enhanced Regulatory Frameworks The regulatory landscape for the hereditary angioedema-therapeutics market is evolving, with enhanced frameworks aimed at expediting the approval of new therapies. Regulatory agencies, such as the FDA, are increasingly adopting streamlined processes for the review of treatments targeting rare diseases. This shift is likely to facilitate faster access to innovative therapies for patients suffering from HAE. Additionally, the introduction of programs like Breakthrough Therapy Designation may encourage pharmaceutical companies to invest in HAE treatments, knowing that they can navigate the approval process more efficiently. As a result, the market may experience a surge in new product launches, ultimately benefiting patients and healthcare providers. ### Increased Focus on Personalized Medicine The shift towards personalized medicine is reshaping the hereditary angioedema-therapeutics market. Tailoring treatments to individual patient profiles enhances therapeutic outcomes and minimizes adverse effects. This trend is particularly relevant in HAE, where genetic variations can influence treatment response. As healthcare providers increasingly adopt personalized approaches, the demand for diagnostic tools and targeted therapies is expected to rise. The market may see a surge in the development of companion diagnostics that identify suitable candidates for specific therapies. This focus on personalized medicine could potentially lead to a more efficient allocation of healthcare resources, ultimately benefiting patients and healthcare systems alike. ### Rising Incidence of Hereditary Angioedema The hereditary angioedema-therapeutics market is experiencing growth due to the increasing incidence of HAE in the US. Recent estimates suggest that HAE affects approximately 1 in 10,000 to 1 in 50,000 individuals, leading to a heightened demand for effective therapeutic options. As awareness of the condition grows among healthcare providers and patients, the need for specialized treatments becomes more pronounced. This rising incidence is likely to drive investments in research and development, as pharmaceutical companies seek to address the unmet needs of patients suffering from HAE. Furthermore, the increasing recognition of HAE as a serious health concern may lead to more comprehensive healthcare policies and funding, further bolstering the hereditary angioedema-therapeutics market. ### Growing Investment in Rare Disease Research Investment in research for rare diseases, including hereditary angioedema, is on the rise, positively impacting the hereditary angioedema-therapeutics market. With the increasing recognition of HAE as a rare but serious condition, funding from both public and private sectors is becoming more accessible. Initiatives aimed at fostering innovation in rare disease therapeutics are likely to accelerate the development of new treatments. In the US, the Orphan Drug Act provides incentives for companies to develop therapies for rare diseases, which may further stimulate market growth. This influx of investment not only supports the development of novel therapies but also enhances patient access to existing treatments. ## Future Outlook The [Hereditary Angioedema Therapeutics Market](https://www.marketresearchfuture.com/reports/hereditary-angioedema-therapeutics-market-12163) is projected to grow at a 4.1% CAGR from 2025 to 2035, driven by advancements in treatment options and increasing patient awareness. **New opportunities:** - Development of personalized treatment plans leveraging genetic profiling. Expansion of telehealth services for remote patient monitoring. Investment in educational programs for healthcare providers on HAE management. By 2035, the market is expected to achieve substantial growth, reflecting enhanced treatment accessibility and innovation. ## Segment Insights ### By Type: Type I (Largest) vs. Type II (Fastest-Growing) In the US hereditary angioedema-therapeutics market, Type I is the most prevalent segment, commanding a significant share among treatment types. As a well-established classification, Type I therapies have secured a strong foothold due to their effectiveness and widespread recognition within the medical community. Conversely, Type II is emerging rapidly, appealing to a niche yet growing patient demographic, as ongoing research and development efforts bolster its visibility and acceptance. Growth trends in this segment are largely driven by advances in biotechnology, with innovative therapies emerging that cater specifically to the needs of Type II patients. Increased awareness of hereditary angioedema and improved diagnostic capabilities are also contributing factors. As a result, Type II is positioned to experience rapid growth, benefiting from heightened investment in research and a supportive regulatory framework encouraging new therapeutic options. Type I: Dominant vs. Type II: Emerging Type I therapies dominate the market due to their established efficacy and broad recognition among healthcare providers. These treatments have been the cornerstone of managing hereditary angioedema for years, allowing for strong patient adherence and satisfaction. On the other hand, Type II therapies are emerging as alternatives that address the specific needs of patients who may not respond as well to Type I treatments. This segment is characterized by ongoing research and innovative therapeutic solutions, aimed at improving management strategies and patient outcomes. As investments in R&D for Type II continue to grow, this segment is expected to gain a more significant market presence, driven by its potential to offer effective alternatives and a robust pipeline of new therapies. ### By Drug Class: C1 Esterase Inhibitor (Largest) vs. Selective Bradykinin B2 Receptor Antagonist (Fastest-Growing) In the US hereditary angioedema-therapeutics market, the market share is notably dominated by C1 Esterase Inhibitor, which has established itself as the leading drug class due to its efficacy in managing acute attacks. Selective Bradykinin B2 Receptor Antagonist follows as a significant player, demonstrating a growing interest from healthcare providers and patients alike. Kallikrein Inhibitor and Others contribute to the market but occupy smaller shares, making C1 Esterase Inhibitor and Selective Bradykinin B2 Receptor Antagonist the focus of this segment. The growth trends for these drug classes are influenced by a combination of factors including an increasing awareness of hereditary angioedema, advancements in drug development, and a rising patient population seeking effective treatment. There is a substantial emphasis on innovative therapies, particularly for Selective Bradykinin B2 Receptor Antagonist, which is gaining momentum as clinicians recognize its potential benefits over traditional treatments. The competitive landscape continues to evolve, fostering an environment conducive to research and development efforts aimed at enhancing treatment options for patients. C1 Esterase Inhibitor (Dominant) vs. Selective Bradykinin B2 Receptor Antagonist (Emerging) C1 Esterase Inhibitor continues to hold a dominant position in the US hereditary angioedema-therapeutics market, recognized for its ability to rapidly alleviate symptoms during an acute attack. This drug class is well-received among practitioners for its established safety profile and effectiveness. On the other hand, Selective Bradykinin B2 Receptor Antagonist is emerging as a crucial alternative, particularly for patients who may not respond optimally to traditional therapies. It offers a new mechanism of action that appeals to both physicians and patients, highlighting the need for innovative solutions tailored to individual needs. The growing adoption of Selective Bradykinin B2 Receptor Antagonist reflects an important shift towards more personalized approaches in treating hereditary angioedema. ### By Treatment: Prophylaxis (Largest) vs. On-demand (Fastest-Growing) In the US hereditary angioedema-therapeutics market, the treatment segment is predominantly driven by prophylaxis, which commands the largest market share. Prophylaxis treatments have established themselves as the cornerstone for managing hereditary angioedema due to their effectiveness in preventing acute attacks. In contrast, on-demand therapies, while currently smaller in market share, are gaining traction as they provide immediate relief and are increasingly recognized for their essential role in acute management. Growth trends within this segment are particularly promising for on-demand therapies, which are categorized as the fastest-growing option due to rising patient awareness and the adaptability of these treatments. Factors such as innovation in drug formulations and enhanced accessibility have contributed to the rise of on-demand therapies. Additionally, the changing landscape of patient needs emphasizes the importance of flexible treatment modalities, boosting the demand for on-demand solutions, while prophylaxis continues to serve as the standard of care. Prophylaxis (Dominant) vs. On-demand (Emerging) Prophylaxis treatments are currently dominant in the US hereditary angioedema-therapeutics market, primarily focusing on long-term prevention strategies to reduce the frequency and severity of angioedema attacks. These therapies are often preferred by patients for their consistent effectiveness and reliability, leading to a robust market presence. Conversely, on-demand treatments, while emerging, are crucial for immediate relief during acute attacks, showcasing rapid innovation in delivery mechanisms and formulations. The growing recognition of the importance of personalized patient care is further driving the emergence of on-demand solutions. As healthcare providers increasingly adapt to individualized treatment regimens, both prophylaxis and on-demand therapies are expected to coexist and complement each other in enhancing patient outcomes. ### By Route of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing) Within the US hereditary angioedema-therapeutics market, the route of administration segment is characterized by three prominent values: Intravenous, Subcutaneous, and Oral. Intravenous administration holds the largest market share, favored for its rapid onset of action and efficacy in acute treatment scenarios. Conversely, Subcutaneous administration has emerged as the fastest-growing route due to its ease of use, patient preference, and advancements in formulization that allow for self-administration, which is becoming increasingly popular among patients seeking convenience and autonomy. Growth trends for these routes of administration are driven by significant factors such as the rising awareness of hereditary angioedema and the associated treatment options. The demand for patient-friendly formulations has stimulated interest in Subcutaneous options, which promote better adherence and quality of life for patients. In contrast, Intravenous treatments remain critical for acute episodes, reinforcing their importance in the therapeutic landscape. As innovation continues, this segment is expected to evolve, accommodating both efficacy and patient-centric preferences. Intravenous (Dominant) vs. Subcutaneous (Emerging) Intravenous administration is the dominant method in the US hereditary angioedema-therapeutics market, primarily due to its ability to deliver immediate relief during acute angioedema attacks, ensuring rapid therapeutic effects. This method is often preferred in clinical settings where intense monitoring and rapid response are essential. On the other hand, Subcutaneous administration is emerging rapidly, with a focus on convenience and self-management. Patients favor this route as it offers a practical and less invasive alternative, enabling them to manage their conditions effectively at home. The increasing development of easy-to-use devices for self-injection and the reduced need for healthcare provider visits further bolster the appeal of Subcutaneous therapies, positioning them as a significant part of future treatment paradigms. ### By Distribution Channel: Hospital Pharmacy (Largest) vs. Online Pharmacy (Fastest-Growing) In the US hereditary angioedema-therapeutics market, the distribution of market share among the different channels reveals that Hospital Pharmacy takes the lead, accounting for a significant portion. Retail Pharmacies also play a crucial role, but their share is notably less compared to hospitals. Online Pharmacies are emerging as a notable player, gradually capturing attention and market share in this therapeutics segment. Growth trends in this segment indicate a shift towards Online Pharmacies, which are recognized for their convenience and accessibility, appealing particularly to younger demographics and tech-savvy patients. Hospital Pharmacies continue to dominate due to their established infrastructure and relationships with healthcare providers, while Retail Pharmacies are adapting to the e-commerce trend to maintain competitiveness. Hospital Pharmacy (Dominant) vs. Online Pharmacy (Emerging) Hospital Pharmacy remains a dominant force in the US hereditary angioedema-therapeutics market due to its ability to provide specialized care and immediate access to treatments. Hospitals have integrated these therapeutics into their care protocols, ensuring that patients receive timely and effective treatment. Conversely, Online Pharmacies are emerging rapidly, driven by the increasing preference for home delivery and online consultations. They offer advantages such as convenience and often lower prices, making them attractive to patients who seek easy access to their medications. As the market evolves, the competition between these two channels is intensifying, each adapting to meet the changing needs of patients. ## Competitive Benchmarking The hereditary angioedema-therapeutics market is characterized by a dynamic competitive landscape, driven by increasing awareness of the condition and advancements in treatment options. Key players such as Takeda Pharmaceutical Company Limited (Japan), BioCryst Pharmaceuticals, Inc. (US), and CSL Behring (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Takeda focuses on innovation and expanding its product portfolio, while BioCryst emphasizes strategic partnerships to bolster its research capabilities. CSL Behring, on the other hand, is concentrating on regional expansion and optimizing its supply chain to improve accessibility to therapies. Collectively, these strategies contribute to a competitive environment that is increasingly focused on patient-centric solutions and technological advancements.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. The collective influence of these key players shapes the competitive dynamics, as they engage in continuous innovation and strategic collaborations to meet the evolving needs of patients. In October BioCryst Pharmaceuticals, Inc. (US) announced a collaboration with a leading biotechnology firm to develop next-generation therapies for hereditary angioedema. This partnership is strategically significant as it aims to leverage advanced technologies and expertise, potentially accelerating the development of innovative treatment options. Such collaborations may enhance BioCryst's competitive edge by expanding its research capabilities and diversifying its product pipeline. In September Takeda Pharmaceutical Company Limited (Japan) launched a new patient support program designed to improve treatment adherence among hereditary angioedema patients. This initiative underscores Takeda's commitment to patient-centric care and reflects a broader trend in the industry towards enhancing patient engagement. By providing comprehensive support, Takeda aims to strengthen its market position and foster long-term relationships with patients and healthcare providers. In August CSL Behring (US) expanded its manufacturing capabilities in the US to increase the production of its therapies for hereditary angioedema. This strategic move is likely to enhance supply chain reliability and ensure timely access to treatments for patients. By investing in local manufacturing, CSL Behring not only addresses demand but also positions itself favorably in a competitive landscape where supply chain efficiency is paramount. As of November current trends in the hereditary angioedema-therapeutics market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technology, and supply chain reliability. This transition may redefine how companies position themselves in the market, emphasizing the importance of delivering high-quality, effective therapies. ## Recent News & Developments The US Hereditary Angioedema Therapeutics Market has seen significant developments recently. In June 2023, CSL Behring announced progress in its gene therapy development for hereditary angioedema, showcasing advancements in reducing treatment frequency for patients while enhancing efficacy. Takeda Pharmaceutical reported elevated market performance due to the successful launch of its new therapies, which have gained traction among healthcare professionals and patients for their improved safety profiles. In terms of mergers and acquisitions, Emergent BioSolutions completed its acquisition of a small biotech firm focused on rare diseases, including hereditary angioedema, in July 2023. Furthermore, Biocryst Pharmaceuticals achieved a market valuation growth following its innovative product launches; this has solidified its presence in the American market, contributing to an overall market expansion. Over the past two to three years, the market has also seen heightened competition and increased investment in Research and Development as companies such as Amgen and Regeneron Pharmaceuticals emphasize novel therapeutics aimed at improving patient outcomes. Government support through funding for cutting-edge therapies has further stimulated market activity, promising a robust growth landscape for the industry moving forward. ## Report Scope | MARKET SIZE 2024 | 1761.4(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1833.62(USD Million) | | MARKET SIZE 2035 | 2739.7(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.1% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Takeda Pharmaceutical Company Limited (JP), CSL Behring (US), Shire (US), Pharming Group N.V. (NL), BioCryst Pharmaceuticals, Inc. (US), Sobi (SE), Ferring Pharmaceuticals (CH), Grifols S.A. (ES) | | Segments Covered | Type, Drug Class, Treatment, Route of Administration, Distribution Channel | | Key Market Opportunities | Advancements in gene therapy and monoclonal antibodies enhance treatment options in the hereditary angioedema-therapeutics market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the hereditary angioedema-therapeutics market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US hereditary angioedema-therapeutics market in 2024?** A: The market valuation was $1761.4 Million in 2024. **Q: What is the projected market valuation for the US hereditary angioedema-therapeutics market by 2035?** A: The projected valuation for 2035 is $2739.7 Million. **Q: What is the expected CAGR for the US hereditary angioedema-therapeutics market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 4.1%. **Q: Which drug class had the highest valuation in the US hereditary angioedema-therapeutics market in 2024?** A: The C1 Esterase Inhibitor drug class had a valuation of $600.0 Million in 2024. **Q: What are the projected valuations for Type I and Type II hereditary angioedema by 2035?** A: Type I is projected to reach $1600.0 Million, while Type II is expected to reach $1139.7 Million by 2035. **Q: Which route of administration is anticipated to have the highest valuation in the US hereditary angioedema-therapeutics market by 2035?** A: The subcutaneous route is anticipated to reach $1100.0 Million by 2035. **Q: What distribution channel had the highest valuation in 2024 for the US hereditary angioedema-therapeutics market?** A: The hospital pharmacy distribution channel had a valuation of $704.56 Million in 2024. **Q: Which key player is associated with the development of therapies for hereditary angioedema?** A: Takeda Pharmaceutical Company Limited is one of the key players in the development of therapies for hereditary angioedema. **Q: What was the valuation of the on-demand treatment segment in the US hereditary angioedema-therapeutics market in 2024?** A: The on-demand treatment segment was valued at $761.4 Million in 2024. **Q: What is the projected growth for the Kallikrein Inhibitor drug class by 2035?** A: The Kallikrein Inhibitor drug class is projected to reach $600.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-hereditary-angioedema-therapeutics-market-16742*